Drugs for Overactive Bladder
March 20, 2023 (Issue: 1672)
In overactive bladder, involuntary bladder contractions
due to detrusor overactivity result in urinary
urgency, frequency, nocturia, and incontinence.
The prevalence of the disorder increases with age.
Nonpharmacologic treatment, including...more
- DJ Lightner et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol 2019; 202:558. doi:10.1097/ju.0000000000000309
- EA Gormley et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188:2455. doi:10.1016/j.juro.2012.09.079
- WS Reynolds et al. Comparative effectiveness of anticholinergic therapy for overactive bladder in women: a systematic review and meta-analysis. Obstet Gynecol 2015; 125:1423. doi:10.1097/aog.0000000000000851
- SL Gray et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175:401. doi:10.1001/jamainternmed.2014.7663
- B Welk and E McArthur. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int 2020;126:183. doi:10.1111/bju.15040
- G Araklitis et al. Cognitive effects of anticholinergic load in women with overactive bladder. Clin Interv Aging 2020; 15:1493. doi:10.2147/cia.s252852
- Clinical consensus statement: association of anticholinergic medication use and cognition in women with overactive bladder. Female Pelvic Med Reconstr Surg 2021; 27:69. doi:10.1097/spv.0000000000001008
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Mirabegron (Myrbetriq) for overactive bladder. Med Lett Drugs Ther 2013; 55:13.
- Vibegron (Gemtesa) for overactive bladder. Med Lett Drugs Ther 2021; 63:67.
- D Staskin et al. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 2020; 204:316. doi:10.1097/ju.0000000000000807
- C Kelleher et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol 2018; 74:324. doi:10.1016/j.eururo.2018.03.020
- CR Chapple et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol 2020; 77:119. doi:10.1016/j. eururo.2019.09.024
- MJ Drake et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol 2016; 70:136. doi:10.1016/j.eururo.2016.02.030
- S Herschorn et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 2017; 120:562. doi:10.1111/bju.13882
- C Gratzke et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur Urol 2018; 74:501. doi:10.1016/j.eururo.2018.05.005
- K Kosilov et al. Influence of the short-term intake of high doses of solifenacin and trospium on cognitive function and health-related quality of life in older women with urinary incontinence. Int Neurourol J 2018; 22:41. doi:10.5213/inj.1834996.498
- Botox for overactive bladder. Med Lett Drugs Ther 2013; 55:31.
- DR Ellington et al. Combined tolterodine and vaginal estradiol cream for overactive bladder symptoms after randomized single-therapy treatment. Female Pelvic Med Reconstr Surg 2016; 22:254. doi:10.1097/spv.0000000000000256
- H Chen et al. Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial. Urology 2017; 100:59. doi:10.1016/j.urology.2016.11.008
- ES Rovner et al. Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study. Low Urin Tract Symptoms 2018; 10:221. doi:10.1111/luts.12169
- WD Steers et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 2007; 100:337. doi:10.1111/j.1464-410x.2007.06980.x
- HFA Moossdorff-Steinhauser and B Berghmans. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. Neurourol Urodyn 2013; 32:206. doi:10.1002/nau.22296
- KM Peters et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182:1055. doi:10.1016/j.juro.2009.05.045
- A Vollstedt and J Gilleran. Update on implantable PTNS devices. Curr Urol Rep 2020; 21:28. doi:10.1007/s11934-020-00980-5
- S Gandhi et al. Long-term outcomes of sacral neuromodulation for lower urinary tract dysfunction: a 23-year experience. Neurourol Urodyn 2021; 40:461. doi:10.1002/nau.24583
- CL Amundsen et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol 2018; 74:66. doi:10.1016/j.eururo.2018.02.011
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
